Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/72751
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Haller, D. | - |
dc.contributor.author | Tabernero, J. | - |
dc.contributor.author | Maroun, J. | - |
dc.contributor.author | de Braud, F. | - |
dc.contributor.author | Price, T. | - |
dc.contributor.author | Van Cutsem, E. | - |
dc.contributor.author | Hill, M. | - |
dc.contributor.author | Gilberg, F. | - |
dc.contributor.author | Rittweger, K. | - |
dc.contributor.author | Schmoll, H. | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Journal of Clinical Oncology, 2011; 29(11):1465-1471 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.issn | 1527-7755 | - |
dc.identifier.uri | http://hdl.handle.net/2440/72751 | - |
dc.description.abstract | PURPOSE: This multicenter, randomized trial compared capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil (FU) and folinic acid (FA) as adjuvant therapy for patients with stage III colon cancer. PATIENTS AND METHODS: Patients who had undergone curative resection were randomly assigned to XELOX (oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1,000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 24 weeks) or a standard bolus FU/FA adjuvant regimen (Mayo Clinic for 24 weeks or Roswell Park for 32 weeks). The primary study end point was disease-free survival (DFS). RESULTS: The intention-to-treat population comprised 1,886 patients; 944 patients were randomly assigned to XELOX and 942 to FU/FA (Mayo Clinic, n _ 664; Roswell Park, n _ 278). After 57 months of follow-up for the primary analysis, 295 patients (31.3%) in the XELOX group had relapsed, developed a new primary colon cancer, or died compared with 353 patients (37.5%) in the FU/FA group (hazard ratio [HR] for DFS, 0.80; 95% CI, 0.69 to 0.93; P _ .0045). The 3-year DFS rate was 70.9% with XELOX and 66.5% with FU/FA. The HR for overall survival (OS) for XELOX compared to FU/FA was 0.87 (95% CI, 0.72 to 1.05; P _ .1486). The 5-year OS for XELOX and FU/FA were 77.6% and 74.2%, respectively. Follow-up is ongoing. Preplanned multivariate and subgroup analyses supported the robustness of these findings. CONCLUSION: The addition of oxaliplatin to capecitabine improves DFS in patients with stage III colon cancer. XELOX is an additional adjuvant treatment option for these patients. | - |
dc.description.statementofresponsibility | Daniel G. Haller, Josep Tabernero, Jean Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Frank Gilberg, Karen Rittweger and Hans-Joachim Schmoll | - |
dc.language.iso | en | - |
dc.publisher | Amer Soc Clinical Oncology | - |
dc.rights | © 2011 by American Society of Clinical Oncology | - |
dc.source.uri | http://dx.doi.org/10.1200/jco.2010.33.6297 | - |
dc.subject | Humans | - |
dc.subject | Colonic Neoplasms | - |
dc.subject | Organoplatinum Compounds | - |
dc.subject | Fluorouracil | - |
dc.subject | Leucovorin | - |
dc.subject | Deoxycytidine | - |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | - |
dc.subject | Neoplasm Staging | - |
dc.subject | Disease-Free Survival | - |
dc.subject | Chemotherapy, Adjuvant | - |
dc.subject | Proportional Hazards Models | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | Aged, 80 and over | - |
dc.subject | Middle Aged | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.subject | Capecitabine | - |
dc.subject | Oxaliplatin | - |
dc.title | Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1200/JCO.2010.33.6297 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Price, T. [0000-0002-3922-2693] | - |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.